Literature DB >> 25308172

miR-122--a key factor and therapeutic target in liver disease.

Simonetta Bandiera1, Sébastien Pfeffer2, Thomas F Baumert3, Mirjam B Zeisel4.   

Abstract

Being the largest internal organ of the human body with the unique ability of self-regeneration, the liver is involved in a wide variety of vital functions that require highly orchestrated and controlled biochemical processes. Increasing evidence suggests that microRNAs (miRNAs) are essential for the regulation of liver development, regeneration and metabolic functions. Hence, alterations in intrahepatic miRNA networks have been associated with liver disease including hepatitis, steatosis, cirrhosis and hepatocellular carcinoma (HCC). miR-122 is the most frequent miRNA in the adult liver, and a central player in liver biology and disease. Furthermore, miR-122 has been shown to be an essential host factor for hepatitis C virus (HCV) infection and an antiviral target, complementary to the standard of care using direct-acting antivirals or interferon-based treatment. This review summarizes our current understanding of the key role of miR-122 in liver physiology and disease, highlighting its role in HCC and viral hepatitis. We also discuss the perspectives of miRNA-based therapeutic approaches for viral hepatitis and liver disease.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HBV; HCC; HCV; Hepatitis; Liver disease pathogenesis; miR-122

Mesh:

Substances:

Year:  2014        PMID: 25308172     DOI: 10.1016/j.jhep.2014.10.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  226 in total

1.  Clinical development of hepatitis C virus host-targeting agents.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Lancet       Date:  2017-01-11       Impact factor: 79.321

Review 2.  Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer.

Authors:  Timothy Ming-Hun Wan; Deepak Narayanan Iyer; Lui Ng
Journal:  Histol Histopathol       Date:  2019-10-16       Impact factor: 2.303

Review 3.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

4.  Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.

Authors:  Stefan Mockenhaupt; Stefanie Grosse; Daniel Rupp; Ralf Bartenschlager; Dirk Grimm
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

Review 5.  [Research progress of miRNAs targeting GSK-3β in regulation of hepatocellular carcinoma invasion and metastasis].

Authors:  Song-Qi He; Bin Wen; Guan-Xin Chen; Hai-Tao Sun; Jia-Ling Sun; Xue-Mei Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-01-20

Review 6.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

7.  Pigmy MicroRNA: surveillance cops in Therapies kingdom.

Authors:  Utpal Bhadra; Pradipta Patra; Jagamohan Chhatai; Manika Pal-Bhadra
Journal:  Mol Med       Date:  2016-09-28       Impact factor: 6.354

8.  Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways.

Authors:  Da Jung Kim; Hyewon Chung; Sang Chun Ji; SeungHwan Lee; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  Metabolomics       Date:  2019-02-27       Impact factor: 4.290

Review 9.  MicroRNAs in injury and repair.

Authors:  Cory V Gerlach; Vishal S Vaidya
Journal:  Arch Toxicol       Date:  2017-05-13       Impact factor: 5.153

10.  Gld2 activity is regulated by phosphorylation in the N-terminal domain.

Authors:  Christina Z Chung; Nileeka Balasuriya; Emad Manni; Xuguang Liu; Shawn Shun-Cheng Li; Patrick O'Donoghue; Ilka U Heinemann
Journal:  RNA Biol       Date:  2019-05-05       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.